PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) is making precision oncology its primary development strategy, concentrating capital and clinical resources on the CD228V antibody-drug conjugate while seeking partnerships to advance other programs with less direct spending.
CD228V, a second-generation antibody-drug conjugate targeting melanotransferrin/CD228 in solid tumors, is now the company’s principal strategic priority. Medicus plans to initially pursue clinical proof-of-concept in melanoma, particularly in patients with relapsed or refractory disease.
The program has an active U.S. Investigational New Drug application and a first-in-human Phase 1 clinical study, NCT06799533. Medicus is pairing the clinical program with translational and biomarker work intended to assess CD228V’s activity.
The company believes demonstrating proof-of-concept in melanoma could support subsequent development of CD228V in other solid tumors expressing CD228.
The shift also changes how Medicus intends to deploy resources across SkinJect and Teverelix, with management pursuing strategic partnerships and other capital-efficient structures to preserve development opportunities outside its primary oncology program.
“Our objective is increasingly clear,” Executive Chairman and Chief Executive Officer Raza Bokhari stated. “We are concentrating our capital and organizational resources on programs where we believe focused clinical development and execution may create the greatest value and improve patient outcomes, while using strategic partnerships and other capital-efficient structures to preserve and unlock the potential value of other programs.”
For SkinJect, Medicus is narrowing its development strategy toward Gorlin syndrome rather than broadly targeting sporadic or nodular basal cell carcinoma.
The U.S. Food and Drug Administration has authorized the company to begin SKNJCT-005, an NDA-enabling registrational Phase 2b study involving patients with Gorlin syndrome who have multiple basal cell carcinomas.
Gorlin syndrome is a rare autosomal dominant disease in which patients can develop numerous basal cell carcinoma lesions over their lifetimes, often requiring repeated surgery or other lesion-directed procedures.
Medicus sees the narrower rare-disease strategy as potentially offering advantages over the more competitive sporadic basal cell carcinoma market. The company identified potential FDA Orphan Drug Designation and Rare Pediatric Disease designation, as well as rare-disease-based pricing, among those opportunities.
For Teverelix, Medicus plans to prioritize an optimized Phase 2 acute urinary retention program involving approximately 126 patients and PRECISION-E2, a Phase 2a study in women with symptomatic endometriosis.
The company intends to continue developing the scientific and strategic positioning of Teverelix in advanced prostate cancer through potential partnerships rather than making that indication a primary internal development priority.
The portfolio changes concentrate Medicus’ direct capital allocation around programs management views as having stronger near-term risk-adjusted potential, with CD228V placing precision oncology at the center of the company’s longer-term development strategy.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.